Stocktoria

Gain Therapeutics, Inc. GANX

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-03-18

Gain Therapeutics, Inc. statistics & valuation

Market cap$74.6M
P / B4.0×
Return on equity-108.6%
Net cash$20.4M
Enterprise value USD$54.2M
Earnings yield EBIT/EV-34.5%
Return on capital-96.1%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202020212022202320242025
Operating margin (%)
-12047.50% -8379.80% -12688.10% -40328.30% 202020212022202320242025
Return on equity (%)
-57.70% -39.90% -93.20% -177.00% -278.10% -108.60% 202020212022202320242025
Shares outstanding
3.5M 11.9M 11.9M 16.2M 27.1M 42.1M 202020212022202320242025
Net debt ($)
-$6.8M -$36.2M -$6.7M -$11.2M -$9.9M -$20.4M 202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
-37.30% -35.60% -73.00% -119.70% -168.40% -88.40% 202020212022202320242025
Free cash flow margin (%)
-11291.40% -7551.70% 202020212022202320242025
Debt / equity (×)
0.12× 0.02× 0.03× 0.05× 0.06× 0.02× 202020212022202320242025
EPS ($)
-$1.33 -$1.37 -$1.48 -$1.71 -$0.89 -$0.61 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin——-40328.3%-12688.1%-8379.8%-12047.5%
Net margin——-40354.3%-12555.1%-8418.9%-12387.7%
FCF margin————-7551.7%-11291.4%
Return on assets-88.4%-168.4%-119.7%-73.0%-35.6%-37.3%
Return on equity-108.6%-278.1%-177.0%-93.2%-39.9%-57.7%
Debt / equity0.02×0.06×0.05×0.03×0.02×0.12×
Current ratio6.632.973.595.1114.784.25

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.